Emalex Biosciences

Tim Rudolphi recently joined Emalex as our Chief Commercial Officer. He is responsible for developing and executing our commercial strategy and product launches. His extensive commercial expertise and broad leadership experience in large and small pharma organizations are vital to our commercial preparations. Welcome Tim! https://lnkd.in/gY8VkkSX

Enjoy!

Best wishes to our CEO, Eric Messner, who is running a 100-mile trail race this weekend in support of the Tourette Association of America!

87% of adults living with Tourette Syndrome (TS) experience physical pain. 72% of adults living with TS have felt discriminated against. 58% of adults with TS have participated in self-harming behaviors. Tourette Syndrome is often diagnosed in childhood. Tics may lessen and even disappear by late adolescence. Yet there are people with Tourette's who continue to have persistent tics as adults. They experience social and work difficulties that have an impact on their mental health and overall well-being (as reported in the Tourette Association of America’s Impact Survey). During Tourette Syndrome Awareness Month, learn more about this neurological condition and how you can help by visiting https://tourette.org/

Physical Pain Bullying Isolation Discrimination These are some of the issues children with Tourette Syndrome (TS) may experience in their everyday life, as reported in the Tourette Association of America’s Impact Survey. Tourette Syndrome Awareness Month (May 15-June 15) is an opportunity to learn more about this neurological condition, characterized by physical and vocal tics, that is commonly undiagnosed and often misunderstood. Here are some quick facts about Tourette’s from the Centers for Disease Control and Prevention: -- Boys are three times more likely than girls to have TS. -- Adolescents (12-17 years old) are more likely to have a TS diagnosis than children in younger age groups. -- More than 80% of children with TS have at least one additional mental, behavioral, or developmental disorder. -- Two years is the average time for a child to receive a diagnosis of TS from the initial awareness of tics. Some tics lessen over time and may dissipate in early adulthood. However, there is no cure for TS. Information and resources for children with TS can be found here: https://lnkd.in/gcAn8tAj

Caring for a child with Tourette Syndrome (TS), a neurological condition characterized by physical and vocal tics, can be challenging. There are doctor’s appointments and medications to manage. Issues at school to navigate with Individualized Educational Plans/ 504 plans and other support services such as counseling and tutoring. That’s just the beginning. When you add in the day-to-day issues, along with work and household responsibilities, parents can become quickly overwhelmed. In support of people impacted by TS and tic disorders and their families, the Tourette Association of America hosts an annual conference called TIC-CON. This year’s TIC-CON takes place May 31-June 2 in Dallas. Families are invited to learn more about research and treatment options, connect with others living with TS and tic disorders, and explore programs and services. Details and registration are available here: https://lnkd.in/eMEFF2KP

Central nervous system (CNS) disorders are extremely challenging to treat. The brain’s natural physical and biochemical wall, called the blood-brain barrier, provides it with almost superhuman protection. The better we understand how the brain develops and operates, the more insight we have on how to effectively penetrate the blood-brain barrier to treat neurological disorders. Researchers from the University of Michigan, the Weizmann Institute of Science, and the University of Pennsylvania have developed the first stem cell culture method that produces a full model of the early stages of the human CNS. “Models like this will open doors for fundamental research to understand early development of the human central nervous system and how it could go wrong in different disorders,” said Jianping Fu, University of Michigan professor of mechanical engineering and corresponding author of the study in Nature. In addition, the model could provide critical insight, resulting in better treatment strategies for CNS disorders. Details about the study can be found here: https://lnkd.in/g3Nse6Kx

Hope to see you there!

A Neurology Today article highlights our positive phase 2b D1AMOND study data that will be presented at the American Academy of Neurology (AAN) Annual Meeting in Denver, April 13-18. Read more about this potential therapeutic for Tourette’s syndrome: https://lnkd.in/gDebzxvy

On National Doctors’ Day, Emalex recognizes the more than 48,000 active physicians in Illinois and over 1M active physicians nationwide who improve lives and communities everyday.